In vitro activity of fluconazole, itraconazole, voriconazole and terbinafine against fungi causing onychomycosis

Clinical and Experimental Dermatology

Volumn 35, Issue 6, 2010, Pages 658-663

  Bueno, J G ^a   Martinez, C ^a   Zapata, B ^a   Sanclemente, G ^a   Gallego, M ^a   Mesa, A C ^a  

^a UNIVERSIDAD DE ANTIOQUIA   (Colombia)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE; ITRACONAZOLE; TERBINAFINE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA; DERMATOPHYTE; FUNGUS; FUNGUS ISOLATION; FUSARIUM; FUSICOCCUM DIMIDIATUM; HUMAN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; ONYCHOMYCOSIS; PRIORITY JOURNAL; SCYTALIDIUM HYALINUM;

ANALYSIS OF VARIANCE; ANTIFUNGAL AGENTS; ARTHRODERMATACEAE; CANDIDA; COLOMBIA; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUCONAZOLE; FUNGI; FUSARIUM; HUMANS; ITRACONAZOLE; MICROBIAL SENSITIVITY TESTS; NAPHTHALENES; ONYCHOMYCOSIS; PYRIMIDINES; TRIAZOLES;

EID: 77954317439     PISSN: 03076938     EISSN: 13652230     Source Type: Journal    
DOI: 10.1111/j.1365-2230.2009.03698.x     Document Type: Article

References (26)

1. Sehgal VN, Jain S. Onychomycosis: clinical perspective. Int J Dermatol 2000 39: 241 249.
2. Sanclemente G, Mahecha M, Guzmán C. Enfermedades de la piel más frecuentes en la consulta dermatológica del hospital universitario San Vicente de Paúl y del Hospital Infantil, Medellín, Colombia 1999. Acta Med Colomb 2001 26: 240 244.
3. Freedberg I, Eisen A, Wolff K et al. Fitzpatrick's Dermatology in General Medicine.
4. Hay RJ. The future of onychomycosis therapy may involve a combination of approaches. Br J Dermatol 2001 145 (Suppl. 60 3 8.
5. Cuenca-Estrella M, Moore CB, Barchiesi F et al. Multicenter evaluation of the reproducibility of the proposed antifungal susceptibility testing method for fermentative yeasts of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFSTEUCAST). Clin Microbiol Infect 2003 9: 467 474.
6. Committee for Clinical Laboratory Standards. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi; Approved Standard. M38-A.
7. English MP. Nails and fungi. Br J Dermatol 1976 94: 697 701.
8. De Hoog GS, Guarro J, Gené J, Figueras MJ. Hyphomycetes. In: Atlas of Clinical Fungi (De Hoog GS, Guarro J, eds).
9. Lee SB, Taylor JW. Isolation of DNA from fungal mycelia and single spores. In: PCR Protocols. A Guide to Methods and Applications (Innis MA, Gelfand DH, Sninsky JJ, White TJ, eds).
10. O'Donnell K, Kistler HC, Cigelnik E et al. Multiple evolutionary origins of the fungus causing Panama disease of banana: concordant evidence from nuclear and mitochondrial gene genealogies. Proc Natl Acad Sci USA 1998 95: 2044 2049.
11. Ohst T, de Hoog S, Presber W et al. Origins of microsatellite diversity in the Trichophyton rubrum-T. violaceum clade (dermatophytes). J Clin Microbiol 2004 42: 4444 4448.
12. Alastruey-Izquierdo A, Cuenca-Estrella M, Monzon A, Rodriguez-Tudela JL. Prevalence and susceptibility testing of new species of Pseudallescheria and Scedosporium in a collection of clinical mold isolates. Antimicrob Agents Chemother 2007 51: 748 751.
13. Santos DA, Hamdan JS. Evaluation of broth microdilution antifungal susceptibility testing conditions for Trichophyton rubrum. J Clin Microbiol 2005 43: 1917 1920.
14. Gupta AK, Kohli Y. In vitro susceptibility testing of ciclopirox, terbinafine, ketoconazole and itraconazole against dermatophytes and nondermatophytes, and in vitro evaluation of combination antifungal activity. Br J Dermatol 2003 149: 296 305.
15. Ghannoum MA, Hajjeh RA, Scher R et al. A large-scale North American study of fungal isolates from nails: the frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns. J Am Acad Dermatol 2000 43: 641 648.
16. Espinel-Ingroff A. Mechanisms of resistance to antifungal agents: yeasts and filamentous fungi. Rev Iberoam Micol 2008 25: 101 106.
17. Seebacher C, Brasch J, Abeck D et al. Onychomycosis Mycoses 2007 50: 321 327. (Pubitemid 46920268)
18. Alvarez MI, Gonzalez LA, Castro LA. Onychomycosis in Cali, Colombia. Mycopathologia 2004 158: 181 186.
19. Zuluaga A, De Bedout C, Tabares A et al. Comportamiento de los agentes etiologicos de las onicomicosis en un laboratorio de micologia de referencia (Medellín 1994-2003). Med Cutan Ibero Lat Am 2005 33: 251 256.
20. Darkes MJ, Scott LJ, Goa KL. Terbinafine: a review of its use in onychomycosis in adults. Am J Clin Dermatol 2003 4: 39 65.
21. Garcia-Martos P, Dominguez I, Marin P et al. Onychomycoses caused by nondermatophytic filamentous fungi in Cadiz. Enferm Infecc Microbiol Clin 2000 18: 319 324.
22. Guilhermetti E, Takahachi G, Shinobu CS et al. Fusarium spp. as agents of onychomycosis in immunocompetent hosts. Int J Dermatol 2007 46: 822 826.
23. Ortoneda M, Capilla J, Javier Pastor F et al. In vitro interactions of licensed and novel antifungal drugs against Fusarium spp. Diagn Microbiol Infect Dis 2004 48: 69 71. (Pubitemid 38167503)
24. Tosti A, Piraccini BM, Lorenzi S et al. Treatment of nondermatophyte mold and Candida onychomycosis. Dermatol Clin 2003 21: 491 497.
25. Garcia-Effron G, Gomez-Lopez A, Mellado E et al. In vitro activity of terbinafine against medically important non-dermatophyte species of filamentous fungi. J Antimicrob Chemother 2004 53: 1086 1089.
26. Carrillo-Muñoz AJ, Giusiano G, Guarro J et al. In vitro activity of voriconazole against dermatophytes, Scopulariopsis brevicaulis and other opportunistic fungi as agents of onychomycosis. Int J Antimicrob Agents 2007 30: 157 161.